当前位置: 首页 >> 检索结果
201. A randomized prospective open-label controlled trial comparing the performance of a connected monitoring interface versus physical routine monitoring in patients with rheumatoid arthritis.
作者: Yves-Marie Pers.;Verushka Valsecchi.;Thibault Mura.;Safa Aouinti.;Nathalie Filippi.;Sarah Marouen.;Hind Letaief.;Pierre Le Blay.;Michel Autuori.;Dominique Fournet.;Grégoire Mercier.;Rosanna Ferreira.;Christian Jorgensen.
来源: Rheumatology (Oxford). 2021年60卷4期1659-1668页
In RA, telemedicine may allow tight control of disease activity while reducing hospital visits. We developed a smartphone application connected with a physician's interface to monitor RA patients. We aimed to assess the performance of this e-Health solution in comparison with routine practice in the management of patients with RA.
202. Sustained-release diclofenac conjugated to hyaluronate (diclofenac etalhyaluronate) for knee osteoarthritis: a randomized phase 2 study.
作者: Yoshihiro Nishida.;Kazuyuki Kano.;Yuji Nobuoka.;Takayuki Seo.
来源: Rheumatology (Oxford). 2021年60卷3期1435-1444页
To evaluate the efficacy and safety of diclofenac etalhyaluronate (DF-HA) (ONO-5704/SI-613), a novel DF-conjugated hyaluronate, in patients with knee OA in Japan.
203. Sialendoscopy increases saliva secretion and reduces xerostomia up to 60 weeks in Sjögren's syndrome patients: a randomized controlled study.
作者: K Hakki Karagozoglu.;Arjan Vissink.;Tim Forouzanfar.;Jan G A M de Visscher.;Floor Maarse.;Henk S Brand.;Peter M van de Ven.;Derk H Jan Jager.
来源: Rheumatology (Oxford). 2021年60卷3期1353-1363页
To assess the effect of sialendoscopy of the major salivary glands on salivary flow and xerostomia in patients with Sjögren's syndrome (SS).
204. A phase 2 randomized, double-blind, placebo-controlled, proof-of-concept study of oral seletalisib in primary Sjögren's syndrome.
作者: Maria Juarez.;Nieves Diaz.;Geoffrey I Johnston.;Saba Nayar.;Andrew Payne.;Eric Helmer.;Dionne Cain.;Paulette Williams.;Valerie Devauchelle-Pensec.;Benjamin A Fisher.;Roberto Giacomelli.;Jacques-Eric Gottenberg.;Giuliana Guggino.;Marika Kvarnström.;Xavier Mariette.;Wan Fai Ng.;José Rosas.;Juan Sánchez Bursón.;Giovanni Triolo.;Francesca Barone.;Simon J Bowman.
来源: Rheumatology (Oxford). 2021年60卷3期1364-1375页
This phase 2 proof-of-concept study (NCT02610543) assessed efficacy, safety and effects on salivary gland inflammation of seletalisib, a potent and selective PI3Kδ inhibitor, in patients with moderate-to-severe primary Sjögren's syndrome (PSS).
205. Predictors of joint damage progression and stringent remission in patients with established rheumatoid arthritis in clinical remission.
作者: Signe Møller-Bisgaard.;Stylianos Georgiadis.;Kim Hørslev-Petersen.;Bo Ejbjerg.;Merete Lund Hetland.;Lykke Midtbøll Ørnbjerg.;Daniel Glinatsi.;Jakob Møller.;Mikael Boesen.;Kristian Stengaard-Pedersen.;Ole Rintek Madsen.;Bente Jensen.;Jan Alexander Villadsen.;Ellen-Margrethe Hauge.;Philip Bennett.;Oliver Hendricks.;Karsten Asmussen.;Marcin Kowalski.;Hanne Lindegaard.;Henning Bliddal.;Niels Steen Krogh.;Torkell Ellingsen.;Agnete H Nielsen.;Lone Balding.;Anne Grethe Jurik.;Henrik S Thomsen.;Mikkel Østergaard.
来源: Rheumatology (Oxford). 2021年60卷1期380-391页
To study if clinical, radiographic and MRI markers can predict MRI and radiographic damage progression and achievement of stringent remission in patients with established RA in clinical remission followed by a targeted treatment strategy.
206. Variation in the pharmacokinetics of glucosamine in healthy individuals.
作者: Chhavi Asthana.;Gregory M Peterson.;Madhur D Shastri.;Rahul P Patel.
来源: Rheumatology (Oxford). 2021年60卷3期1205-1209页
Clinical trial data for the efficacy of glucosamine in OA are conflicting. Reportedly, Rotta-manufactured glucosamine products are more likely to be effective, and a possible explanation is greater bioavailability than other brands. Specifically, the aim was to compare the steady-state pharmacokinetics of Rotta- and non-Rotta-manufactured glucosamine products in healthy volunteers and examine the interindividual variability.
207. Performance of composite measures used in a trial of etanercept and methotrexate as monotherapy or in combination in psoriatic arthritis.
作者: Laura C Coates.;Joseph F Merola.;Philip J Mease.;Alexis Ogdie.;Dafna D Gladman.;Vibeke Strand.;Leonieke J J van Mens.;Lyrica Liu.;Priscilla K Yen.;David H Collier.;Gregory Kricorian.;James B Chung.;Philip S Helliwell.
来源: Rheumatology (Oxford). 2021年60卷3期1137-1147页
To examine which composite measures are most sensitive to change when measuring psoriatic arthritis (PsA) disease activity, analyses compared the responsiveness of composite measures used in a 48-week randomized, controlled trial of MTX and etanercept in patients with PsA.
208. A patient-initiated DMARD self-monitoring service for people with rheumatoid or psoriatic arthritis: a cost-effectiveness analysis.
作者: Hayley McBain.;Chris Flood.;Michael Shipley.;Abigail Olaleye.;Samantha Moore.;Stanton Newman.
来源: Rheumatology (Oxford). 2021年60卷1期277-287页
To determine whether a patient-initiated DMARD self-monitoring service for people on MTX is a cost-effective model of care for patients with RA or PsA.
209. Efficacy and safety of Sandoz biosimilar rituximab for active rheumatoid arthritis: 52-week results from the randomized controlled ASSIST-RA trial.
作者: Josef S Smolen.;Stanley B Cohen.;Hans-Peter Tony.;Morton Scheinberg.;Alan Kivitz.;Andra Balanescu.;Juan Gomez-Reino.;Liyi Cen.;Johann Poetzl.;Tamas Shisha.;Dmitrij Kollins.
来源: Rheumatology (Oxford). 2021年60卷1期256-262页
This report provides data for the extent of B cell depletion and recovery, efficacy, safety and immunogenicity of Sandoz rituximab (SDZ-RTX; GP2013; Rixathon®) compared with reference rituximab (Ref-RTX) up to week 52 of the ASSIST-RA study.
210. The iCanCope pain self-management application for adolescents with juvenile idiopathic arthritis: a pilot randomized controlled trial.
作者: Chitra Lalloo.;Lauren R Harris.;Amos S Hundert.;Roberta Berard.;Joseph Cafazzo.;Mark Connelly.;Brian M Feldman.;Kristin Houghton.;Adam Huber.;Ronald M Laxer.;Nadia Luca.;Heinrike Schmeling.;Lynn Spiegel.;Lori B Tucker.;Quynh Pham.;Cleo C Davies-Chalmers.;Jennifer N Stinson.
来源: Rheumatology (Oxford). 2021年60卷1期196-206页
To evaluate the feasibility and preliminary effectiveness of iCanCope with Pain (iCanCope), a smartphone-based pain self-management program, in adolescents with JIA. iCanCope featured symptom tracking, goal-setting, pain coping skills and social support.
211. Patient adherence with a smartphone app for patient-reported outcomes in rheumatoid arthritis.
作者: Josh Colls.;Yvonne C Lee.;Chang Xu.;Cassandra Corrigan.;Fengxin Lu.;Georgia Marquez-Grap.;Meredith Murray.;Dong H Suh.;Daniel H Solomon.
来源: Rheumatology (Oxford). 2021年60卷1期108-112页
Electronic patient-reported outcomes (ePROs) transmitted digitally allow patients to communicate with their clinicians and track the activity of chronic diseases, such as RA. Several ePRO smartphone apps have been developed in rheumatology, yet few data have been reported regarding patient adherence. We developed a PRO app for RA and assessed adherence over 6 months.
212. An international, multicentre, double-blind, randomized study (DISSCO): effect of diacerein vs celecoxib on symptoms in knee osteoarthritis.
作者: Jean-Pierre Pelletier.;Jean-Pierre Raynauld.;Marc Dorais.;Louis Bessette.;Eva Dokoupilova.;Frédéric Morin.;Karel Pavelka.;Patrice Paiement.;Johanne Martel-Pelletier.; .
来源: Rheumatology (Oxford). 2020年59卷12期3858-3868页
The objective of this study was to investigate whether diacerein has comparable efficacy with celecoxib in pain reduction for treatment in symptomatic knee OA patients.
213. Early variation of ultrasound halo sign with treatment and relation with clinical features in patients with giant cell arteritis.
作者: Cristina Ponte.;Ana Sofia Serafim.;Sara Monti.;Elisabete Fernandes.;Ellen Lee.;Surjeet Singh.;Jennifer Piper.;Andrew Hutchings.;Eugene McNally.;Andreas P Diamantopoulos.;Bhaskar Dasgupta.;Wolfgang A Schmidt.;Raashid Ahmed Luqmani.
来源: Rheumatology (Oxford). 2020年59卷12期3717-3726页
To compare the ultrasound characteristics with clinical features, final diagnosis and outcome; and to evaluate the halo size following glucocorticoid treatment in patients with newly diagnosed GCA.
214. Preclinical cardiac organ damage during statin treatment in patients with inflammatory joint diseases: the RORA-AS statin intervention study.
作者: Hanna A Os.;Silvia Rollefstad.;Eva Gerdts.;Ester Kringeland.;Eirik Ikdahl.;Anne Grete Semb.;Helga Midtbø.
来源: Rheumatology (Oxford). 2020年59卷12期3700-3708页
Statin treatment has been associated with reduction in blood pressure and arterial stiffness in patients with inflammatory joint diseases (IJD). We tested whether statin treatment also was associated with regression of preclinical cardiac organ damage in IJD patients.
215. Efficacy and safety of upadacitinib in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE): a placebo-controlled phase IIb/III study.
作者: Hideto Kameda.;Tsutomu Takeuchi.;Kunihiro Yamaoka.;Motohiro Oribe.;Mitsuhiro Kawano.;Yijie Zhou.;Ahmed A Othman.;Aileen L Pangan.;Susumu Kitamura.;Sebastian Meerwein.;Yoshiya Tanaka.
来源: Rheumatology (Oxford). 2020年59卷11期3303-3313页
To evaluate upadacitinib efficacy and safety dose response in Japanese patients with active RA and an inadequate response to conventional synthetic DMARDs (csDMARDs).
216. Follow-up results of myositis patients treated with H. P. Acthar gel.
作者: Didem Saygin.;Chester V Oddis.;Galina Marder.;Siamak Moghadam-Kia.;Preeya Nandkumar.;Nicole Neiman.;Sedin Dzanko.;Diane Koontz.;Rohit Aggarwal.
来源: Rheumatology (Oxford). 2020年59卷10期2976-2981页
Idiopathic inflammatory myopathies (IIM) are a group of autoimmune diseases characterized by proximal muscle weakness. H. P. Acthar gel [repository corticotropin injection (RCI)] is a formulation of adrenocorticotropic hormone and has been approved by Food and Drug Administration for use in IIM; however, literature is limited. In this study, we report longitudinal follow-up of myositis patients treated with RCI.
217. Reducing the initial number of rituximab maintenance-therapy infusions for ANCA-associated vasculitides: randomized-trial post-hoc analysis.
作者: Pierre Charles.;Agnès Dechartres.;Benjamin Terrier.;Pascal Cohen.;Stanislas Faguer.;Antoine Huart.;Mohamed Hamidou.;Christian Agard.;Bernard Bonnotte.;Maxime Samson.;Alexandre Karras.;Noémie Jourde-Chiche.;François Lifermann.;Pierre Gobert.;Catherine Hanrotel-Saliou.;Pascal Godmer.;Nicolas Martin-Silva.;Grégory Pugnet.;Marie Matignon.;Olivier Aumaitre.;Jean-François Viallard.;François Maurier.;Nadine Meaux-Ruault.;Sophie Rivière.;Jean Sibilia.;Xavier Puéchal.;Luc Mouthon.;Loïc Guillevin.; .
来源: Rheumatology (Oxford). 2020年59卷10期2970-2975页
The randomized, controlled MAINRITSAN2 trial was designed to compare the capacity of an individually tailored therapy [randomization day 0 (D0)], with reinfusion only when CD19+ lymphocytes or ANCA had reappeared, or if the latter's titre rose markedly, with that of five fixed-schedule 500-mg rituximab infusions [D0 + D14, then months (M) 6, 12 and 18] to maintain ANCA-associated vasculitis (AAV) remissions. Relapse rates did not differ at M28. This ancillary study was undertaken to evaluate the effect of omitting the D14 rituximab infusion on AAV relapse rates at M12.
218. Attainment of treat-to-target endpoints in SLE patients with high disease activity in the atacicept phase 2b ADDRESS II study.
作者: Eric F Morand.;David A Isenberg.;Daniel J Wallace.;Amy H Kao.;Cristina Vazquez-Mateo.;Peter Chang.;Kishore Pudota.;Cynthia Aranow.;Joan T Merrill.
来源: Rheumatology (Oxford). 2020年59卷10期2930-2938页
Low disease activity (LDA) and remission are emerging treat-to-target (T2T) endpoints in SLE. However, the rates at which these endpoints are met in patients with high disease activity (HDA) are unknown. Atacicept, which targets B lymphocyte stimulator and a proliferation-inducing ligand, improved disease outcomes in SLE patients with HDA (SLEDAI-2K ≥10) at baseline in the phase 2b ADDRESS II study. This is a post hoc analysis of T2T endpoints in these patients.
219. Ixekizumab treatment of biologic-naïve patients with active psoriatic arthritis: 3-year results from a phase III clinical trial (SPIRIT-P1).
作者: Vinod Chandran.;Désirée van der Heijde.;Roy M Fleischmann.;Eric Lespessailles.;Philip S Helliwell.;Hideto Kameda.;Ruben Burgos-Vargas.;Janelle S Erickson.;Suchitrita S Rathmann.;Aubrey Trevelin Sprabery.;Julie A Birt.;Catherine L Shuler.;Gaia Gallo.
来源: Rheumatology (Oxford). 2020年59卷10期2774-2784页
The aim was to assess the safety and efficacy of up to 156 weeks of ixekizumab (an IL-17A antagonist) treatment in PsA patients.
220. Conventional versus ultrasound treat to target: no difference in magnetic resonance imaging inflammation or joint damage over 2 years in early rheumatoid arthritis.
作者: Ulf Sundin.;Anna-Birgitte Aga.;Øivind Skare.;Lena B Nordberg.;Till Uhlig.;Hilde B Hammer.;Désirée van der Heijde.;Tore K Kvien.;Siri Lillegraven.;Espen A Haavardsholm.; .
来源: Rheumatology (Oxford). 2020年59卷9期2550-2555页
To investigate whether an ultrasound-guided treat-to-target strategy for early RA would lead to reduced MRI inflammation or less structural damage progression compared with a conventional treat-to-target strategy.
|